로딩 중…
지수 로딩 중…
Biosolution Co.,Ltd.
086820· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩6,510-3.84%
2026-06-19
Price Chart
Biosolution Co.,Ltd.-30.00%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 168.77B KRW |
| Revenue | 15.82B KRW |
| Net Income | 5.88B KRW |
| Total Assets | 66.37B KRW |
| Net Assets | 41.94B KRW |
| Employees | 88 |
| Value | |
| P/E | 28.70x |
| P/B | 4.02x |
| P/S | 10.67x |
| FCF Yield | -0.89% |
| Profitability | |
| ROE | 14.02% |
| ROA | 8.86% |
| Op. Margin | -2.57% |
| Revenue Growth | 19.87% |
| Financial Health | |
| Debt Ratio | 158.23% |
| Total Debt | 18.22B KRW |
| FCF | -1.50B KRW |
| Cash | 11.15B KRW |
| Current Ratio | 0.81x |
| Performance | |
| 1Y Return | -30.00% |
| 1M Return | -22.96% |
| From 52W High | -51.60% |
| 1Y MDD | -49.73% |
| Trading | |
| Volume | 101,902 shares |
| Foreign Own. | 3.19% |
| Per Share | |
| EPS | 27 KRW |
| BPS | 1,625 KRW |
Company Info
Established in 2000 as a cell therapy developer, the company changed its name in 2016, listed on KOSDAQ in 2018, and established local subsidiaries in China and Australia during the current period. It operates businesses in cell therapies, human stem cell-derived materials, peptide cosmetic ingredients, human tissue models, and alternative testing services. Following the commercialization of autologous cell therapies, the company is developing allogeneic cell therapies to expand commercialization and versatility. It is also expanding cosmetic ingredients through market expansion via human tissue model certification and joint research. BIOSOLUTIONS is headquartered in Nowon-gu, Seoul.